MAIN ARTICLE
Strong earnings fail to settle investors’ concerns
For the quarter ended September 30, 2026, Apollo reported consolidated net profit of 6.30 billion rupees, up from 4.77 billion rupees a year earlier. That was close to the 6.36 billion rupees expected by analysts surveyed by LSEG. Overall operating revenue rose 23% to roughly 76.15 billion rupees, and consolidated EBITDA increased 29% to approximately 11.91 billion rupees. These figures underscore demand for higher-complexity medical procedures and a sizeable business with continuing momentum.
Yet its share price moved in the opposite direction. The 3.4% decline was an observation during the morning session, not a closing-price outcome. Apollo’s underperformance against a rising Nifty 50 suggests that investors are scrutinising the durability of margins and the cash demands of expansion rather than merely celebrating the pace of last year’s profit growth.
New hospitals impose costs before delivering returns
Citi, as cited by Reuters, estimated that newer facilities recorded 348 million rupees in losses and pre-operating expenses, whereas mature hospitals retained an operating margin of 25.8%. Across the hospital services business, the EBITDA margin was approximately 24%, narrowing by about 60 basis points. The figures capture the different economics of a well-established medical centre and a newly commissioned one.















